T Cell News and Research

Latest T Cell News and Research

New oral agent shows promise in treatment of relapsed multiple myeloma

A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies, a clinical trial conducted by researchers at Dana-Farber Cancer Institute and around the world has found.

30 Aug 2023

New mechanism of action discovered for pulmonary distress in immunocompromised patients

When an immunocompromised person's system begins to recover and produce more white blood cells, it's usually a good thing – unless they develop a potentially deadly inflammatory condition.

30 Aug 2023

Unlocking tumor immune evasion: IL1RL1+ Treg cells and CAFs collaborate for immunotherapy resistance

Researchers demonstrated that the crosstalk between IL1RL1+ regulatory T-cells (Treg) and cancer-associated fibroblasts (CAFs) drives the tissue repairing.

30 Aug 2023

Researchers develop new, modular strategy for T-cell-based immunotherapy

Immunotherapies for cancer aim to induce the immune system to combat cancer cells more effectively.

25 Aug 2023

Study explores lipid and metabolic alterations in HIV/TB co-infected patients

Researchers investigated the differential impact of HIV/tuberculosis co-infection on lipid and metabolic profiles.

23 Aug 2023

Current and future strategies for vaccinating against invasive pneumococcal disease

Researchers reviewed the immune mechanisms employed by existing vaccines for invasive pneumococcal disease.

23 Aug 2023

NCCN publishes new resource on options, benefits of care approaches for pediatric Hodgkin lymphoma

The National Comprehensive Cancer Network today announced the publication of NCCN Guidelines for Patients®: Hodgkin Lymphoma in Children.

22 Aug 2023

Glycans and GBPs: How their interplay shapes immunity in infection and autoimmune diseases

Researchers discuss the regulatory roles of glycans and glycan-binding proteins in modulating immune responses.

21 Aug 2023

New artificial DNA structures can target and destroy cancer cells

A new study highlights the potential of artificial DNA structures that, when fitted with antibodies, instruct the immune system to specifically target cancerous cells.

18 Aug 2023

Regulation of cytotoxic T-cell differentiation and exhaustion by mTOR signaling

Researchers describe molecular signalling regulated by mTOR among memory and exhausted cytotoxic CD8+ T lymphocytes.

18 Aug 2023

Rutgers scientists discover first lipid vascular 'zip code' in the lungs

Researchers at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School (NJMS), together with other collaborating groups, have discovered the first lipid vascular 'ZIP code' in the lungs.

16 Aug 2023

Deep learning framework DeepAIR could improve understanding of adaptive immunity

Researchers presented a deep learning framework, DeepAIR, to accurately predict adaptive immune receptor (AIR)-antigen binding.

15 Aug 2023

Novel multi-epitope subunit vaccine induces robust immune response against Epstein-Barr virus

Scientists have developed a lymph node-targeted multi-epitope subunit vaccine that induces strong humoral and cellular immune responses against EBV in mice.

14 Aug 2023

Unveiling hidden threats: clustering loops in CAR-T cells impact cancer therapy

How complementarity-determining region (CDR) loops in the single-chain variable fragment (scFv) influence chimeric antigen receptor (CAR)-T cell behavior.

14 Aug 2023

Study explores the diverse expression patterns of T cell priming markers across cancers

A recent study explored transcriptomics of T-cell priming markers (TPMs) across different cancers.

10 Aug 2023

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.

From MaxCyte, Inc. 10 Aug 2023

Deep-learning technology could help scientists to develop personalized immunotherapies and vaccines

Deep-learning technology developed by a team of Johns Hopkins engineers and cancer researchers can accurately predict cancer-related protein fragments that may trigger an immune system response.

9 Aug 2023

Neoantigen discovery sheds light on cancer immunogenicity

Researchers reported a proteogenomic approach to investigate fresh solid melanoma tumor material.

4 Aug 2023

Study reports the first protein-based diagnostic signature to discriminate MIS-C from Kawasaki Disease and other common infections

Researchers explore the distinguishing features of MIS-C as compared to other inflammatory-infectious syndromes in children.

4 Aug 2023

Deep learning improves protein design by 10x

The key to understanding proteins -; such as those that govern cancer, COVID-19, and other diseases -; is quite simple. Identify their chemical structure and find which other proteins can bind to them. But there's a catch.

3 Aug 2023

Previous
1
...
12
13
14
15
16
17
18
...
2902
Next

T Cell News and Research

Latest T Cell News and Research

New oral agent shows promise in treatment of relapsed multiple myeloma

New mechanism of action discovered for pulmonary distress in immunocompromised patients

Unlocking tumor immune evasion: IL1RL1+ Treg cells and CAFs collaborate for immunotherapy resistance

Researchers develop new, modular strategy for T-cell-based immunotherapy

Study explores lipid and metabolic alterations in HIV/TB co-infected patients

Current and future strategies for vaccinating against invasive pneumococcal disease

NCCN publishes new resource on options, benefits of care approaches for pediatric Hodgkin lymphoma

Glycans and GBPs: How their interplay shapes immunity in infection and autoimmune diseases

New artificial DNA structures can target and destroy cancer cells

Regulation of cytotoxic T-cell differentiation and exhaustion by mTOR signaling

Rutgers scientists discover first lipid vascular 'zip code' in the lungs

Deep learning framework DeepAIR could improve understanding of adaptive immunity

Novel multi-epitope subunit vaccine induces robust immune response against Epstein-Barr virus

Unveiling hidden threats: clustering loops in CAR-T cells impact cancer therapy

Study explores the diverse expression patterns of T cell priming markers across cancers

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

Deep-learning technology could help scientists to develop personalized immunotherapies and vaccines

Neoantigen discovery sheds light on cancer immunogenicity

Study reports the first protein-based diagnostic signature to discriminate MIS-C from Kawasaki Disease and other common infections

Deep learning improves protein design by 10x

Immunology eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in